Type 2 diabetes is not associated with an altered plaque phenotype among patients undergoing carotid revascularization. A histological analysis of 1455 carotid plaques

Atherosclerosis

Volumn 235, Issue 2, 2014, Pages 418-423

  Scholtes, Vincent P W ^a   Peeters, Wouter ^a   van Lammeren, Guus W ^a   Howard, Dominic P J ^b   de Vries, Jean Paul P M ^c   de Borst, Gert Jan ^a   Redgrave, Jessica N ^b   Kemperman, Hans ^a   Schalkwijk, Casper G ^d,e   den Ruijter, Hester M ^a   de Kleijn, Dominique P V ^a   Moll, Frans L ^a   Rothwell, Peter M ^b   Pasterkamp, Gerard ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b RADCLIFFE INFIRMARY   (United Kingdom)

^c ST ANTONIUS HOSPITAL   (Netherlands)

^d Laboratory of Metabolism and Vascular Medicine   (Netherlands)

^e MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Carotid endarterectomy; Carotid plaque; Diabetes; Histology

Indexed keywords

ADVANCED GLYCATION END PRODUCT; CHEMOKINE; COLLAGEN; CYTOKINE; ORAL ANTIDIABETIC AGENT;

ADULT; AGED; ARTERY CALCIFICATION; ARTICLE; CAPILLARY DENSITY; CAROTID ATHEROSCLEROSIS; CAROTID ENDARTERECTOMY; CONTROLLED STUDY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHENOTYPE; PRIORITY JOURNAL; REVASCULARIZATION; SMOOTH MUSCLE FIBER; ATHEROSCLEROTIC PLAQUE; COMPLICATION; PATHOLOGY; PATHOPHYSIOLOGY;

DIABETES MELLITUS, TYPE 2; ENDARTERECTOMY, CAROTID; PLAQUE, ATHEROSCLEROTIC;

EID: 84921447893     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.05.941     Document Type: Article

References (31)

1. Go A.S., Mozaffarian D., Roger V.L., Benjamin E.J., Berry J.D., Borden W.B., et al. Heart disease and stroke statistics - 2013 update: a report from the American Heart Association. Circulation 2013, 127:e6-e245.
2. Mokdad A.H., Ford E.S., Bowman B.A., Dietz W.H., Vinicor F., Bales V.S., et al. Prevalence of obesity, diabetes, and obesity-related health risk factors. JAMA 2001, 2003(289):76-79.
3. Fox C.S., Coady S., Sorlie P.D., D'Agostino R.B., Pencina M.J., Vasan R.S., et al. Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study. Circulation 2007, 115:1544-1550.
4. Beckman J.A., Creager M.A., Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002, 287:2570-2581.
5. Bhatt D.L., Eagle K.A., Ohman E.M., Hirsch A.T., Goto S., Mahoney E.M., et al. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA 2010, 304:1350-1357.
6. Cho E., Rimm E.B., Stampfer M.J., Willett W.C., Hu F.B. The impact of diabetes mellitus and prior myocardial infarction on mortality from all causes and from coronary heart disease in men. JAm Coll Cardiol 2002, 40:954-960.
7. Jamrozik K., Broadhurst R.J., Forbes S., Hankey G.J., Anderson C.S. Predictors of death and vascular events in the elderly: the Perth Community Stroke Study. Stroke 2000, 31:863-868.
8. Juutilainen A., Lehto S., Rönnemaa T., Pyörälä K., Laakso M. Type 2 diabetes as a "coronary heart disease equivalent": an 18-year prospective population-based study in Finnish subjects. Diab Care 2005, 28:2901-2907.
9. Verhoeven B.A.N., Velema E., Schoneveld A.H., de Vries J.P.P.M., de Bruin P., Seldenrijk C.A., et al. Athero-express: differential atherosclerotic plaque expression of mRNA and protein in relation to cardiovascular events and patient characteristics. Rationale and design. Eur J Epidemiol 2004, 19:1127-1133.
10. Hellings W.E., Pasterkamp G., Vollebregt A., Seldenrijk C.A., De Vries J.-P.P.M., Velema E., et al. Intraobserver and interobserver variability and spatial differences in histologic examination of carotid endarterectomy specimens. JVasc Surg 2007, 46:1147-1154.
11. Teerlink T., Barto R., Ten Brink H.J., Schalkwijk C.G. Measurement of Nepsilon-(carboxymethyl)lysine and Nepsilon-(carboxyethyl)lysine in human plasma protein by stable-isotope-dilution tandem mass spectrometry. Clin Chem 2004, 50:1222-1228.
12. Teerlink T. Measurement of asymmetric dimethylarginine in plasma: methodological considerations and clinical relevance. Clin Chem Lab Med 2005, 43:1130-1138.
13. Verhoeven B.A.N., Moll F.L., Koekkoek J.A.F., van der Wal A.C., de Kleijn D.P.V., de Vries J.P.P.M., et al. Statin treatment is not associated with consistent alterations in inflammatory status of carotid atherosclerotic plaques: a retrospective study in 378 patients undergoing carotid endarterectomy. Stroke 2006, 37:2054-2060.
14. Hellings W.E., Pasterkamp G., Verhoeven B.A.N., De Kleijn D.P.V., De Vries J.-P.P.M., Seldenrijk K.A., et al. Gender-associated differences in plaque phenotype of patients undergoing carotid endarterectomy. JVasc Surg 2007, 45:289-296. discussion 296-7.
15. Redgrave J.N., Lovett J.K., Syed A.B., Rothwell P.M. Histological features of symptomatic carotid plaques in patients with impaired glucose tolerance and diabetes (oxford plaque study). Cerebrovasc Dis 2008, 26:79-86.
16. Kanter J.E., Johansson F., LeBoeuf R.C., Bornfeldt K.E. Do glucose and lipids exert independent effects on atherosclerotic lesion initiation or progression to advanced plaques?. Circ Res 2007, 100:769-781.
17. Pasterkamp G. Methods of accelerated atherosclerosis in diabetic patients. Heart 2013, 99:743-749.
18. Spagnoli L.G., Mauriello A., Palmieri G., Santeusanio G., Amante A., Taurino M. Relationships between risk factors and morphological patterns of human carotid atherosclerotic plaques. A multivariate discriminant analysis. Atherosclerosis 1994, 108:39-60.
19. Cipollone F., Iezzi A., Fazia M., Zucchelli M., Pini B., Cuccurullo C., et al. The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control. Circulation 2003, 108:1070-1077.
20. Burke A.P., Kolodgie F.D., Zieske A., Fowler D.R., Weber D.K., Varghese P.J., et al. Morphologic findings of coronary atherosclerotic plaques in diabetics: a postmortem study. Arterioscler Thromb Vasc Biol 2004, 24:1266-1271.
21. Moreno P.R., Murcia A.M., Palacios I.F., Leon M.N., Bernardi V.H., Fuster V., et al. Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus. Circulation 2000, 102:2180-2184.
22. Hellings W.E., Peeters W., Moll F.L., Piers S.R.D., van Setten J., Van der Spek P.J., et al. Composition of carotid atherosclerotic plaque is associated with cardiovascular outcome: a prognostic study. Circulation 2010, 121:1941-1950.
23. Kolodgie F.D., Gold H.K., Burke A.P., Fowler D.R., Kruth H.S., Weber D.K., et al. Intraplaque hemorrhage and progression of coronary atheroma. NEngl J Med 2003, 349:2316-2325.
24. Golledge J., Greenhalgh R.M., Davies A.H. The symptomatic carotid plaque. Stroke 2000, 31:774-781.
25. Achterberg S., Cramer M.J.M., Kappelle L.J., de Borst G.J., Visseren F.L.J., van der Graaf Y., et al. Patients with coronary, cerebrovascular or peripheral arterial obstructive disease differ in risk for new vascular events and mortality: the SMART study. Eur J Cardiovasc Prev Rehab 2010, 17:424-430.
26. Bernhagen J., Calandra T., Bucala R. Regulation of the immune response by macrophage migration inhibitory factor: biological and structural features. JMol Med (Berl) 1998, 76:151-161.
27. Bernhagen J., Krohn R., Lue H., Gregory J.L., Zernecke A., Koenen R.R., et al. MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat Med 2007, 13:587-596.
28. De Kleijn D.P.V., Moll F.L., Hellings W.E., Ozsarlak-Sozer G., de Bruin P., Doevendans P.A., et al. Local atherosclerotic plaques are a source of prognostic biomarkers for adverse cardiovascular events. Arterioscler Thromb Vasc Biol 2010, 30:612-619.
29. Dandona P., Aljada A., Ghanim H., Mohanty P., Tripathy C., Hofmeyer D., et al. Increased plasma concentration of macrophage migration inhibitory factor (MIF) and MIF mRNA in mononuclear cells in the obese and the suppressive action of metformin. JClin Endocrinol Metab 2004, 89:5043-5047.
30. Brown A., Reynolds L.R., Bruemmer D. Intensive glycemic control and cardiovascular disease: an update. Nat Rev Cardiol 2010, 7:369-375.
31. Camafort M., Alvarez-Rodríguez L.R., Muñoz-Torrero J.F.S., Sahuquillo J.C., López-Jiménez L., Coll R., et al. Glucose control and outcome in patients with stable diabetes and previous coronary, cerebrovascular or peripheral artery disease. Findings from the FRENA Registry. Diabet Med 2011, 28:73-80.